University of Minnesota. Driven to Discover.
A phase 3 trial shows ceftazidime-avibactam "non-inferior" to meropenem.
Fever, crackling in the lungs, high pulse, and low blood oxygen may be predictive.
More than two thirds of adult hospital patients are on the drugs longer than needed.
Using just 1 drug instead of 2 could go a long way in curbing azithromycin use.
A review finds the biomarker cut mortality and antibiotic exposure in patients with acute respiratory infections.
Only 54% of US workers with asthma had received the recommended pneumococcal vaccine.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.